acute promyelocytic leukemia

So central nervous system involvement can be either leptomeningeal, think cranial nerve palsies, headache, confusion, and we look for it in everyone with Burkitts, no exception.

When it floods the marrow, when it floods the blood, it's being referred to as Burkitt leukemia, and older textbooks call it the L3 ALL, like the M3, so APML.

Yeah.

And I mean, we did talk about this as well.

Go listen to that one.

Prostate cancer, and then in the heme world, hemophilia, von Willebrand's, those bone marrow failure disorders, hemoglobin electrophoresis, I'm just going to add that one in there, as well as AML and APL and Hodgkin's lymphoma.

So these really are kind of our big board review podcast that we guys think you guys should listen to.

And so

Prostate cancer.

And then in the heme world, hemophilia, von Willebrand's, those bone marrow failure disorders, hemoglobin electrophoresis, I'm just going to add that one in there, as well as AML and APL and Hodgkin's lymphoma.

So these really are kind of our big board review podcast that we guys think you guys should listen to.

And so good luck with taking your

Both of these are natural supplements and things that are found in nature.

And it converted something that's called APML, promyelocytic leukemia, from a universally lethal leukemia that killed young people.

And it was dramatic because they would hemorrhage to death.

Very tragic.

But this is also if we think about the context, this is coming on the tail end of the COVID pandemic.

And as you also mentioned here, you know, I think it's actually a fairly well designed study as far as the patient populations included, right? Because when we're thinking about how we want to investigate or explore a question that is unanswered, but make sure that we're maintaining an adequate standard of care and a level of of adequate treatment for patients, we have to think about what subgroups might be at increased risk when conducting such a study, right? So APL obviously has a completely different treatment Core binding factor AML we know can be cured in a subset of patients with high-intensity chemotherapy.

FLT3 ITD-TKD mutated AML.

Obviously, the standard of care is to incorporate a FLT3 inhibitor, as we'll talk about later with some of the Venn combinations.